PL2585469T3 - Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy - Google Patents

Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy

Info

Publication number: PL2585469T3
Authority: PL; Poland
Prior art keywords: benzodioxole; heterocyclic compounds; phosphodiesterase inhibitors; benzodioxepine; benzodioxepine heterocyclic
Prior art date: 2010-06-24

Application number

PL11729889T

Other languages

English (en)

Inventor

Simon Feldbæk Nielsen

Original Assignee

Leo Pharma A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-24

Filing date

2011-06-24

Publication date

2017-07-31

2011-06-24 Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S

2017-07-31 Publication of PL2585469T3 publication Critical patent/PL2585469T3/pl

Links

FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 title 1
-1 benzodioxepine heterocyclic compounds Chemical class 0.000 title 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
239000002571 phosphodiesterase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Endocrinology (AREA)

PL11729889T 2010-06-24 2011-06-24 Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy PL2585469T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35820910P	2010-06-24	2010-06-24
EP11729889.3A EP2585469B1 (en)	2010-06-24	2011-06-24	Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
PL2585469T3 true PL2585469T3 (pl)	2017-07-31

Family

ID=44351701

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL11729889T PL2585469T3 (pl)	2010-06-24	2011-06-24	Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy
PL16020112T PL3070091T3 (pl)	2010-06-24	2011-06-24	Pochodne benzodioksolu jako inhibitory fosfodiesterazy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16020112T PL3070091T3 (pl)	2010-06-24	2011-06-24	Pochodne benzodioksolu jako inhibitory fosfodiesterazy

Country Status (29)

Country	Link
US (3)	US8980905B2 (pl)
EP (2)	EP3070091B1 (pl)
JP (2)	JP6174997B2 (pl)
KR (1)	KR101864578B1 (pl)
CN (1)	CN102958937B (pl)
AU (1)	AU2011269429B2 (pl)
BR (1)	BR112012032813B1 (pl)
CA (1)	CA2802895C (pl)
CY (2)	CY1117862T1 (pl)
DK (2)	DK3070091T3 (pl)
ES (2)	ES2584055T3 (pl)
HR (2)	HRP20160919T1 (pl)
HU (2)	HUE030081T2 (pl)
IL (1)	IL223329A (pl)
LT (2)	LT2585469T (pl)
MX (1)	MX2012014131A (pl)
MY (1)	MY157481A (pl)
NZ (1)	NZ603895A (pl)
PL (2)	PL2585469T3 (pl)
PT (2)	PT3070091T (pl)
RS (2)	RS58945B1 (pl)
RU (1)	RU2583787C2 (pl)
SG (1)	SG186140A1 (pl)
SI (2)	SI3070091T1 (pl)
TR (1)	TR201909709T4 (pl)
TW (1)	TWI507410B (pl)
UA (1)	UA109140C2 (pl)
WO (1)	WO2011160632A1 (pl)
ZA (1)	ZA201209031B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014083099A1 (en) *	2012-11-30	2014-06-05	Leo Pharma A/S	A method of inhibiting the expression of il-22 in activated t-cells
JP6785666B2 (ja)	2014-06-23	2020-11-18	レオファーマアクティーゼルスカブ	１，３−ベンゾジオキソール複素環化合物の調製方法
WO2017089347A1 (en)	2015-11-25	2017-06-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
DK3390407T3 (da) *	2015-12-18	2023-11-06	Union Therapeutics As	Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
AU2018286964B2 (en)	2017-06-20	2022-04-14	UNION therapeutics A/S	Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2019115776A1 (en)	2017-12-15	2019-06-20	Leo Pharma A/S	Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
MX2020010999A (es)	2018-04-18	2021-01-20	Constellation Pharmaceuticals Inc	Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en)	2018-05-21	2022-07-20	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
KR20210117300A (ko) *	2019-01-15	2021-09-28	유니온 테라퓨틱스 에이/에스	포스포디에스테라제 억제제를 함유하는 변형 방출 정제 제형
PE20220562A1 (es)	2019-07-24	2022-04-13	Constellation Pharmaceuticals Inc	Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
KR20220041130A (ko) *	2019-07-24	2022-03-31	콘스텔레이션 파마슈티칼스, 인크.	암 치료를 위한 병용 요법에서의 ezh2 억제
CN112552276B (zh) *	2019-09-25	2023-03-21	中国科学院上海药物研究所	苯并氧杂卓-5-酮类化合物及其制备方法和用途
KR20230159485A (ko) *	2021-03-22	2023-11-21	유니온 테라퓨틱스 에이/에스	오리스밀라스트를 사용한 화농땀샘염의 치료
GB202205715D0 (en)	2022-04-19	2022-06-01	Union Therapeutics As	Treatment of neutrophilic dermatoses
GB202306663D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Combination therapy
GB202306662D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Dosage regimen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ290266B6 (cs)	1993-07-02	2002-06-12	Byk Gulden Lomberg Chemische Fabrik Gmbh	Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9507297D0 (en)	1995-04-07	1995-05-31	Rh Ne Poulenc Rorer Limited	New composition of matter
HK1000785A1 (en)	1995-05-19	2006-06-30	Kyowa Hakko Kogyo Co., Ltd	Oxygen-containing heterocyclic compounds
HUP0100042A3 (en) *	1996-05-20	2003-01-28	Darwin Discovery Ltd Cambridge	Benzofuran carboxamides medicaments containing the same and their therapeutic use
AU4967697A (en)	1996-11-19	1998-06-10	Kyowa Hakko Kogyo Co. Ltd.	Oxygenic heterocyclic compounds
JP2005060375A (ja) *	2003-07-28	2005-03-10	Kyowa Hakko Kogyo Co Ltd	含酸素複素環化合物
DE10360792A1 (de)	2003-12-23	2005-07-28	Grünenthal GmbH	Spirocyclische Cyclohexan-Derivate
PL1831227T3 (pl) *	2004-12-17	2013-10-31	Glenmark Pharmaceuticals Sa	Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
PL2114951T3 (pl) *	2007-02-28	2014-10-31	Leo Pharma As	Nowe inhibitory fosfodiesterazy
ZA200905371B (en) *	2007-02-28	2010-10-27	Leo Pharma As	Novel phosphodiesterase Inhibitors
MX2014006812A (es) *	2011-12-21	2014-10-13	Leo Pharma As	[1,2,4] triazolopiridinas y su uso como inhibidores de fosfodiesterasa.

2011
- 2011-06-24 JP JP2013515698A patent/JP6174997B2/ja active Active
- 2011-06-24 EP EP16020112.5A patent/EP3070091B1/en active Active
- 2011-06-24 RU RU2013103079/04A patent/RU2583787C2/ru active
- 2011-06-24 HU HUE11729889A patent/HUE030081T2/en unknown
- 2011-06-24 MY MYPI2012005553A patent/MY157481A/en unknown
- 2011-06-24 US US13/806,659 patent/US8980905B2/en active Active
- 2011-06-24 CA CA2802895A patent/CA2802895C/en active Active
- 2011-06-24 DK DK16020112.5T patent/DK3070091T3/da active
- 2011-06-24 ES ES11729889.3T patent/ES2584055T3/es active Active
- 2011-06-24 RS RS20190851A patent/RS58945B1/sr unknown
- 2011-06-24 PT PT16020112T patent/PT3070091T/pt unknown
- 2011-06-24 AU AU2011269429A patent/AU2011269429B2/en active Active
- 2011-06-24 TW TW100122303A patent/TWI507410B/zh active
- 2011-06-24 PL PL11729889T patent/PL2585469T3/pl unknown
- 2011-06-24 NZ NZ603895A patent/NZ603895A/en unknown
- 2011-06-24 MX MX2012014131A patent/MX2012014131A/es active IP Right Grant
- 2011-06-24 BR BR112012032813-1A patent/BR112012032813B1/pt active IP Right Grant
- 2011-06-24 PL PL16020112T patent/PL3070091T3/pl unknown
- 2011-06-24 CN CN201180031069.5A patent/CN102958937B/zh active Active
- 2011-06-24 SG SG2012088761A patent/SG186140A1/en unknown
- 2011-06-24 PT PT117298893T patent/PT2585469T/pt unknown
- 2011-06-24 SI SI201131743T patent/SI3070091T1/sl unknown
- 2011-06-24 ES ES16020112T patent/ES2733092T3/es active Active
- 2011-06-24 LT LTEP11729889.3T patent/LT2585469T/lt unknown
- 2011-06-24 HU HUE16020112 patent/HUE044301T2/hu unknown
- 2011-06-24 RS RS20160581A patent/RS55104B1/sr unknown
- 2011-06-24 SI SI201130896A patent/SI2585469T1/sl unknown
- 2011-06-24 TR TR2019/09709T patent/TR201909709T4/tr unknown
- 2011-06-24 UA UAA201300812A patent/UA109140C2/uk unknown
- 2011-06-24 EP EP11729889.3A patent/EP2585469B1/en active Active
- 2011-06-24 LT LTEP16020112.5T patent/LT3070091T/lt unknown
- 2011-06-24 HR HRP20160919TT patent/HRP20160919T1/hr unknown
- 2011-06-24 WO PCT/DK2011/000069 patent/WO2011160632A1/en not_active Ceased
- 2011-06-24 KR KR1020137001855A patent/KR101864578B1/ko active Active
- 2011-06-24 DK DK11729889.3T patent/DK2585469T3/en active
2012
- 2012-11-28 IL IL223329A patent/IL223329A/en active IP Right Grant
- 2012-11-29 ZA ZA2012/09031A patent/ZA201209031B/en unknown
2014
- 2014-12-30 US US14/586,681 patent/US9273064B2/en active Active
2015
- 2015-10-01 US US14/872,487 patent/US9637499B2/en active Active
2016
- 2016-03-16 JP JP2016052707A patent/JP2016164168A/ja active Pending
- 2016-07-28 CY CY20161100745T patent/CY1117862T1/el unknown
2019
- 2019-06-21 HR HRP20191136TT patent/HRP20191136T1/hr unknown
- 2019-06-28 CY CY20191100679T patent/CY1122201T1/el unknown

Also Published As

Publication number	Publication date
LT3070091T (lt)	2019-07-25
EP2585469A1 (en)	2013-05-01
SI2585469T1 (sl)	2016-11-30
TWI507410B (zh)	2015-11-11
DK2585469T3 (en)	2016-08-29
TR201909709T4 (tr)	2019-07-22
SG186140A1 (en)	2013-01-30
AU2011269429A1 (en)	2012-12-20
CN102958937A (zh)	2013-03-06
TW201206940A (en)	2012-02-16
CY1122201T1 (el)	2020-11-25
PT2585469T (pt)	2016-08-29
PT3070091T (pt)	2019-07-22
KR20130038341A (ko)	2013-04-17
US20150111915A1 (en)	2015-04-23
CN102958937B (zh)	2016-03-30
NZ603895A (en)	2014-10-31
BR112012032813A2 (pt)	2016-11-08
RS55104B1 (sr)	2016-12-30
JP2016164168A (ja)	2016-09-08
WO2011160632A1 (en)	2011-12-29
HRP20191136T1 (hr)	2019-09-20
HK1182699A1 (zh)	2013-12-06
IL223329A (en)	2017-01-31
HUE044301T2 (hu)	2019-10-28
UA109140C2 (uk)	2015-07-27
LT2585469T (lt)	2016-10-10
CY1117862T1 (el)	2017-05-17
SI3070091T1 (sl)	2019-08-30
RU2583787C2 (ru)	2016-05-10
MX2012014131A (es)	2013-01-29
KR101864578B1 (ko)	2018-06-07
PL3070091T3 (pl)	2019-09-30
MY157481A (en)	2016-06-15
EP3070091B1 (en)	2019-04-17
ES2584055T3 (es)	2016-09-23
US9637499B2 (en)	2017-05-02
HRP20160919T1 (hr)	2016-10-07
EP2585469B1 (en)	2016-05-25
US9273064B2 (en)	2016-03-01
US20130123291A1 (en)	2013-05-16
RU2013103079A (ru)	2014-07-27
EP3070091A1 (en)	2016-09-21
ES2733092T3 (es)	2019-11-27
DK3070091T3 (da)	2019-07-08
JP6174997B2 (ja)	2017-08-02
CA2802895C (en)	2019-05-21
IL223329A0 (en)	2013-02-03
CA2802895A1 (en)	2011-12-29
BR112012032813B1 (pt)	2022-02-01
ZA201209031B (en)	2014-02-26
JP2013529602A (ja)	2013-07-22
RS58945B1 (sr)	2019-08-30
US8980905B2 (en)	2015-03-17
HUE030081T2 (en)	2017-04-28
US20160022657A1 (en)	2016-01-28
AU2011269429B2 (en)	2015-07-09

Publication	Publication Date	Title
IL295518B1 (en)	2023-07-01	Heterocyclic compounds used as pdk1 inhibitors
IL223329A (en)	2017-01-31	Benzodioxole or benzodioxoxine heterocyclic compounds as phosphodiesterase inhibitors
IL225770A0 (en)	2013-06-27	Heterocyclic compounds
AP2013007252A0 (en)	2013-11-30	Heterocyclic compounds as kinase inhibitors
IL221442A0 (en)	2012-10-31	Heterocyclic compound
IL218271A0 (en)	2012-04-30	Heterocyclic compounds as janus kinase inhibitors
ZA201300950B (en)	2014-04-30	Heterocyclic compound
GB201016880D0 (en)	2010-11-17	Phosphodiesterase inhibitors
IL218114A0 (en)	2012-04-30	5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors
IL208136A0 (en)	2010-12-30	Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL223131A0 (en)	2013-02-03	Heterocyclic compounds as janus kinase inhibitors
IL225350A0 (en)	2013-06-27	Converted benzamide compounds
EP2379538A4 (en)	2013-01-02	HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
IL220205A0 (en)	2012-07-31	Heterocyclic compounds as janus kinase inhibitors
BR112013010643A2 (pt)	2016-08-09	compostos heterocíclicos
EP2611806A4 (en)	2014-05-07	HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES
BR112013005210A2 (pt)	2019-09-24	compostos heterocíclicos como inibidores de dgat1
IL213935A0 (en)	2011-07-31	Novel heterocyclic compounds as metap-2 inhibitors
GB201021416D0 (en)	2011-01-26	Novel heterocyclic compounds
GB201009514D0 (en)	2010-07-21	Novel heterocyclic compounds
GB0919817D0 (en)	2009-12-30	Heterocyclic compounds
GB0919816D0 (en)	2009-12-30	Heterocyclic compounds
GB201009730D0 (en)	2010-07-21	Kinase inhibitor compounds